Sage, Biogen
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
Sage rejects Biogen's $469 million takeover offer, says …
4 days ago · Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. Shares of Sage were up 5.3% at $7.48 in early trading.
Other content from reuters.comSage sues Biogen after unsolicited takeover bid | pharmaphorum
Jan 18, 2025 · Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek …
4 days ago · Sage Therapeutics has officially rejected Biogen’s unsolicited takeover bid and will instead undergo a strategic review that could ultimately end up in a transaction of some kind. Sage’s board unanimously rejected the bid, …
Biogen and Sage Therapeutics Announce Global Collaboration to …
Nov 27, 2020 · Upon closing of the transaction, Biogen and Sage will collaborate to further define the development and commercialization strategy for SAGE-324 in essential tremor and, as …
- bing.com › videosWatch full video
Sage seeks injunction after Biogen's unsolicited buyout …
Jan 21, 2025 · Biogen’s offer, at about $469 million, effectively assigns Sage a negative value because the Massachusetts biotech had about $569 million in cash and equivalents at the end of September.
Sage Therapeutics Board of Directors Initiates Review of Strategic ...
Jan 10, 2025 · In addition, Sage announced that its Board has unanimously rejected the unsolicited, nonbinding proposal it received from Biogen Inc. (Nasdaq: BIIB) (“Biogen”) on …
- People also ask
Sage Therapeutics Announces Discontinuation of the …
Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to …
Sage rejects Biogen’s $469m takeover bid
4 days ago · Sage’s board has stated it will consider “strategic alternatives” to maximise shareholder value. Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of …
Biogen proposes to buy remaining stake in Sage in $442 million deal
Jan 10, 2025 · Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up …
Sage Therapeutics and Biogen Announce Topline Results from …
CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of …
- Some results have been removed
